Betrixaban

Drug Profile

Betrixaban

Alternative Names: Bevyxxa; MK-4448; MLN-1021; PRT 021; PRT 054021

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Portola Pharmaceuticals
  • Class Anticoagulants; Antithrombotics; Benzamides; Imines; Pyridines; Small molecules
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Venous thromboembolism
  • Discontinued Stroke

Most Recent Events

  • 23 Jun 2017 Registered for Venous thromboembolism (Prevention) in USA (First global approval) (PO)
  • 28 Dec 2016 Planned Prescription Drug User Fee Act (PDUFA) date for Venous thromboembolism (Prevention) in USA (PO) is 2017-06-24
  • 23 Dec 2016 Preregistration for Venous thromboembolism (Prevention) in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top